ERS/EAACI Statement on severe exacerbations in asthma in adult: facts, priorities and key research questions. by Bourdin, A et al.
 
 
 
 
 
 
Early View 
 
 
 
Task Force Report 
 
 
 
ERS/EAACI Statement on severe exacerbations in 
asthma in adult: facts, priorities and key research 
questions 
 
 
A. Bourdin, L. Bjermer, C. Brightling, G. Brusselle, P. Chanez, F. Chung, A. Custovic, Z. Diamant, S. 
Diver, R. Djukanovic, D. Hamerlijnck, S. Johnston, F. Kanniess, N. Papadopoulos, A. Papi, R. Russell, 
D. Ryan, K. Samitas, T. Thomy, E. Zervas, M. Gaga 
 
 
 
Please cite this article as: Bourdin A, Bjermer L, Brightling C, et al. ERS/EAACI Statement on 
severe exacerbations in asthma in adult: facts, priorities and key research questions. Eur Respir 
J 2019; in press (https://doi.org/10.1183/13993003.00900-2019). 
 
 
 
 
 
 
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is 
published here in its accepted form prior to copyediting and typesetting by our production team. After 
these production processes are complete and the authors have approved the resulting proofs, the article 
will move to the latest issue of the ERJ online. 
 
 
 
Copyright ©ERS 2019 
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
3
2
9
2
8
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
ERS/EAACI Statement on severe exacerbations in asthma in adult: facts, 
priorities and key research questions 
 
A. Bourdin, L. Bjermer, C. Brightling, G. Brusselle, P. Chanez, F. Chung, A. Custovic, Z. 
Diamant, S Diver, R. Djukanovic, D. Hamerlijnck, S. Johnston, F. Kanniess, N. 
Papadopoulos, A. Papi, R. Russell, D Ryan, K. Samitas, T. Thomy, E. Zervas, M Gaga. 
 
TASK-FORCE Sections and Members 
Section 
no 
Section title Participants 
1 Definitions M. Gaga (leader), K. Samitas  
2 
Triggers and risk 
factors 
A. Bourdin (leader) 
2A 
Assessment of risk,  
What is cause and what 
is effect 
A. Bourdin 
2B 
Modifiable vs non-
modifiable factors & 
Mathematical models 
F. Chung 
2C 
Risk Factors and 
epidemiology, 
pheno/geno/endotypes 
I. Horvath 
2D 
Personality type – 
Gender, Psychosocial 
factors. Perception, 
Compliance/adherence 
L. Bjermer, F. Kanniess 
2E Virus / Allergens Z. Diamant, S. Johnston, R. Djukanovic 
2F 
Environmental air 
pollution 
indoor/outdoor 
pollution & 
occupational factors 
G. Brusselle, A. Papi 
2G 
Drugs & irritants / 
Overdose of 2-agonists 
P. Chanez 
2H 
Interaction between 
different trigger factors 
N. Papadopoulos 
3 Acute Management E. Zervas (leader) 
4 Prevention 
C. Brightling (leader), Dermot Ryan, Richard 
Russell and Sarah Diver 
5 
ELF Patient 
perspective 
D. Hamerlijnck, ELP Patient Advisory Group 
ERS senior methodologist T. Tonia 
Literature Search K. Samitas 
 
 
 
Summary 
Despite the use of effective medications to control asthma, severe exacerbations in asthma are 
still a major health risk and require urgent action on the part of the patient and physician to 
prevent a serious outcome such as hospitalization or death. Moreover, severe exacerbations 
are associated with substantial huge healthcare costs, and psychological burden including 
anxiety and fear for patients and their families. The European Academy of Allergy and 
Clinical Immunology (EAACI) and the European Respiratory Society (ERS) set up a Task 
Force (TF) to search for a clear definition of severe exacerbations and to also define research 
questions and priorities. The statement includes comments from patients who were members 
of the TF. 
  
 
1.  INTRODUCTION 
Asthma is one of the most common chronic diseases and its worldwide prevalence has risen 
around 3-fold in recent decades [1]. With the recognition of the inflammatory nature of the 
disease and the introduction of inhaled corticosteroidinhaled corticosteroids, asthma control 
and the quality of life of asthma patients have substantially improved and many deaths have 
been prevented. Nevertheless, patients still face exacerbations of varying severity ranging 
from increased symptoms to life-threatening episodes. And any asthmatic patient may suffer 
severe exacerbation and even die from one. In fact, most exacerbations present in mild  
asthmatics, who are the majority of asthma sufferers [2, 3]. The causes leading to 
exacerbations may be exposure to a triggering agent, lack of or adherence to treatment, the 
inherent severity and hyperresponsiveness of the disease and may be affected by 
comorbidities. Severe exacerbations of asthma likely carry most of the burden of the disease 
through their immediate and delayed-associated risks. Severe exacerbations are exposing 
patients to immediate and delayed side effects of high doses of bronchodilators and systemic 
corticosteroids, and quite often to antibiotics. Absenteeism, presenteeism, care-associated 
risks if admitted (nosocomial infection for example), anxiety and many other issues are 
insufficiently describing the burden of severe exacerbations. Epidemiological data remain 
heterogenous as very different definitions are used in cohorts and in clinical trials. For 
example, in TENOR II, 25.8% of the population reported a severe exacerbation [4]. In the 
MENSA study, among enrolled patients who reported 3.5 ± 2.2 exacerbations before entering 
the study, 17 to 21% were admitted. During the trial, the mean rate of clinically significant 
exacerbation and exacerbation requiring admission fell to 1.74 and 0.10 respectively [5]. 
Unfortunately, asthma deaths still exist. Their rates are low and most of them are seen as 
preventable [6, 7] in westernized countries. This also implies that some are not preventable, 
suggesting a place for new drugs to treat refractory episodes of near fatal asthma.  
Accordingly, both the ERS and the EAACI elicited a task force in 2016 that aims to review 
the most relevant research evidence and the current practice on definition, clinical 
identification of severe exacerbations, triggers and risk factors, management and prevention. 
Subsequently, this document does not contain recommendations for clinical practice but 
offers recommendations for future research. 
 
Methodology 
After the initial meetings the Task Force members decided to address four main research 
questions related to serious exacerbations: 1) what are the available definitions for severe 
exacerbations in asthmatics and what would be an accurate definition, 2) which are the 
trigger factors related to the initiation and severity of exacerbations, 3) what is the best way 
to manage severe exacerbations 4) and finally what is the best strategy to prevent them. 
Specific keywords and MeSH-terms were identified based on several key-references provided 
by the Task Force members, and the corresponding literature search was initiated for all 
sections using the MEDLINE and CENTRAL (Cochrane Library) Databases. Search results 
were extracted in .txt file formats and imported in a specially designed reference management 
software (Reference Manager Version 12) in order to screen for duplicates. Further 
processing of the search results was made in a step-wise approach (as shown in the 
supplementary file flow-charts) based on the title, the abstract, and finally after reading the 
whole text, filtering for date (2000 and onwards), age (adults only), language (only English), 
and type (included: randomized and observational studies and systematic reviews/meta-
analyses, excluded: case reports and letters to the editor). All articles remaining after final 
processing for each section were sent back to the corresponding TF members for final 
evaluation (corresponding flow charts are available as a supplementary file). From this 
sorting of the relevant literature, leaders of the four sections drafted a first version and each 
statement was kept or removed if any concern was expressed and no consensus could be 
found. During the subsequent dedicated meetings, research needs were identified and tables 
and figures were reviewed. 
 
  
2. Definition of severe exacerbations of asthma 
Asthma severity and control have more or less been defined and graded over the years so 
that the definitions are equally understood by all stakeholders [3, 8–10]. This is not yet 
the case for asthma exacerbations where exacerbations are defined as episodes 
characterized by more or less rapid increase in symptoms, sufficient to require a change 
in treatment [3, 11]. Severe exacerbations are usually defined based on use of systemic, 
usually oral corticosteroids (OCS), emergency care visits and/or hospitalizations [1], 
while in some clinical studies reductions in lung function (peak expiratory flow [PEF] or 
forced expiratory volume in one second [FEV1]) of more than 20 or 30% have also been 
included in the definition. (Table 1) It must be noted that patient perception and easy 
access to rescue corticosteroids and emergency care facilities may confound the definition 
and so may the retrospective collection of data. The ERS/ATS statement on exacerbations 
released in 2009 [12] defines severe exacerbations as events that require urgent action on 
the part of the patient and physician to prevent a serious outcome, i.e. hospitalization or 
death. However, there is subjectivity in the perception of severity and moreover, many 
studies have shown that the risk of severe exacerbation is associated with a multitude of 
factors.  These factors include (1) the level of asthma control, (2) asthma severity based 
on ERS/ATS definition [3], (3) lung function, (4) the presence of comorbidities, (5) the 
psychosocial status (to assess the ability to seek help in case of clinical worsening), (6) 
previous history of near fatal attacks and (7) response to treatment. Such factors seem 
important to guide treatment decisions and, importantly, decisions regarding 
hospitalizations. Moreover, prediction models assessing future risk of exacerbations in 
adult asthma patients have been proposed, such as the one published by Miller et al, based 
on the TENOR cohort [13]. However, the applicability of such models has not been 
examined in large studies and needs to be assessed prospectively. Composite scores have 
been developed for use in other acute respiratory conditions, for example the CURB-65 or 
PSI score for pneumonia or GENEVA score for pulmonary embolism, and they greatly 
help clinicians in treatment decisions and are important for the safety of the patients. All 
TF members in their practice consider severe exacerbations of asthma as a significant 
worsening of the disease that require OCS treatment for at least 5 days.  In the ERS/ATS 
task force in 2009, a three-day course of OCS was the recommended definition for 
clinical trials. This small difference was supported by all TF members as it may 
differentiate from patients with episodes of loss of control requiring short courses (e.g. 1-
2 days) of OCS and from temporary increase of maintenance treatment to improve the 
control of their disease. These patients may have an accumulated use of OCS over time 
equivalent to someone with repeated exacerbations but will not be reported as such. 
Whether 3 or 5 days of OCS is more accurate for discriminating a mild from a severe 
exacerbation will probably not be addressable in terms of evidence. 1) Herein we report 
an expert-based opinion that definitely not intends to change the definition used in trials 
in order to keep them comparable and 2) as the harmfulness of cumulative doses of 
corticosteroids is obvious above 0.5 g per year [14], a five-days based definition would 
make better fit this OCS-associated risk with the threshold of two exacerbations. 
Although variable among countries and systems, emergency visit or hospitalization, the 
TF members base hospitalization or initiation of treatment with OCS on the GINA or BTS 
recommendations to improve standardization. It seems that it would be important to 
develop, test and use a composite score that takes into consideration the patient’s 
previous health status, the presence of comorbidities, history of severe or near fatal 
exacerbations, adherence to treatment, psychosocial status, level of control and of 
course, response to treatment-the latter is already factored into asthma exacerbation 
management guidelines- rather than just clinical severity at presentation and PEF or 
spirometry values. 
TABLE 1: Examples of definitions of severe exacerbation in asthma patients used in the 
literature. 
Author Definition of severe 
exacerbation 
Comment 
GINA 2019 [1]
 
Exacerbations of asthma are 
episodes characterized by a 
progressive increase in 
symptoms of shortness of 
breath, cough, wheezing or chest 
tightness and progressive 
decrease in lung function, i.e. 
they represent a change from the 
patient‟s usual status that is 
sufficient to require a change in 
treatment. Definition based on 
symptoms (“talks in words, sits 
hunched forward, agitated”), 
clinical findings (RR>30/min, 
BPM>120/min, SAT<90%, use 
of accessory muscles) and lung 
function (PEF< 50% pref.)  
GINA proposes an accurate 
definition of exacerbations of 
asthma. Regarding severe 
exacerbations, GINA does not 
define exact criteria by which to 
distinguish severity levels 
Reddel et al 
(ERS/ATS 2009) 
[12]
 
Severe asthma exacerbations are 
defined as events that require 
urgent action on the part of the 
patient and physician to prevent 
a serious outcome, such as 
hospitalization or death from 
asthma. The definition should 
include at least 1 of the 
following: 
a. Use of systemic 
corticosteroids or an 
increase from a stable 
maintenance dose, for at least 3 
days.  
b. A hospitalization or 
emergency department (ED) 
visit because of asthma, 
requiring systemic 
corticosteroids 
 
Strength: This is the most 
commonly used definition 
Weakness: it  relies on patient 
and doctor subjective 
assessment, there are no hard 
criteria for deterioration 
Custovic et al 
(EAACI 2013)[9]
 
No specific definition provided Strength: The taskforce stresses 
the need for a consensus 
definition of asthma 
exacerbation that could usefully 
guide treatment. 
Weakness: It is not really a 
definition 
O‟Byrne et al 2009 
[15]
 
Defined as events requiring 
hospitalization or emergency 
Strengths and weaknesses same 
as those of  Ref  [12] (ERS/ATS 
treatment due to worsening of 
asthma, or death due to asthma. 
Emergency treatment was 
defined as treatment of acute 
airway obstruction with 
systemic corticosteroids and 
nebulized or parenteral 
bronchodilators given at a 
healthcare institution. 
2009)  
Green et al [16], 
Pauwels et al 
(FACET study) [17]
 
Decrease in morning PEF >30% 
on 2 or more consecutive days, 
or deterioration in symptoms 
needing OCS 
Strengths: Adds an objective 
limit in addition to the need for 
OCS or the vague 
“deterioration”  
Weakness: 30% decrease is not 
universally severe, no reference 
to length of time 
 
Jayaram et al 2006 
[18]
 
Course of OCS as determined by 
study investigator 
Weakness: No objective criteria 
given („determined by study 
investigator‟) 
Demoly P 2004 [19]
 
Hospitalization was 
unanimously recognized as the 
first criterion for severe 
exacerbations. A decrease in 
peak expiratory flow of more 
than 30% below the baseline 
value on two consecutive days 
and an episode requiring 
systemic corticosteroids were 
the next criteria. 
This survey emphasizes the 
complexity of the notions of 
asthma control and exacerbation 
 
Strengths: This survey 
emphasizes the complexity of 
the notions of asthma control 
and exacerbation and reflects 
real life practice. Uses an 
objective measure and length of 
time  
Weakness: No hard criteria 
Fuhlbrigge 2013 
(NIH workshop) [20]
 
An exacerbation is a worsening 
of asthma requiring the use of 
systemic 
corticosteroids (or for patients 
on a stable maintenance dose, an 
increase in the use of 
systemic corticosteroids) to 
prevent a serious outcome (The 
subcommittee does not endorse 
severity stratification in the core 
outcome definition) 
 
Strengths and weaknesses same 
as ref [12].
 
Addition: increase in use of 
systemic steroid dose in patients 
already on steroids 
Castro et al 2010 
[21]
 
Those requiring systemic 
corticosteroids or 
doubling of ICS dose 
Weakness: No criteria given for 
„requiring‟; „doubling of 
ICS dose‟  
 
Murphy et al 2010 
[22]
 
Defined as episodes requiring 
medical 
Strengths and weaknesses same 
as ref [12]. 
intervention [hospital admission, 
emergency department 
presentation, unscheduled 
doctor visit or the use of oral 
corticosteroids (OCS)] 
 
 
 
 
3. TRIGGERS AND RISK FACTORS 
3A. Assessment of risk: what is cause and what is effect? 
The prevention of exacerbations is probably the most important aim for patients with asthma 
and health care professionals. In order to achieve this aim, it is important to plan  the re-
assessment of asthma patients and treatment adjustments because of the immediate risks (i.e. 
acute respiratory failure, death) and future risks (recurrence of exacerbations, decline in lung 
function, and side effects of treatments) [1]. Routine management strategies assess asthma 
control based on clinical symptoms, history of exacerbations and pulmonary function testing. 
In addition, in experienced centers, strategies guided by airway hyperresponsiveness (BHR) 
or sputum eosinophilia may provide benefit for preventing future exacerbations [16, 23]. In 
contrast, the use of fractional exhaled nitric oxide (FENO) as a surrogate marker in asthma 
management is still inconclusive [24–26] except during pregnancy [27]. A recent meta-
analysis found more supportive results deserving further evaluations [28]. 
Since a previous exacerbation has been shown to be an important risk factor for future 
exacerbations (even though this concept has been challenged) [29], the “frequent exacerbator” 
likely represents an important clinical phenotype; and asthma treatment should aim to modify 
what might look like an irreversible cycle [30]. For this purpose, multiple initiatives have 
investigated and weighed the importance of individual traits in predicting recurrent 
exacerbations. Many other characteristics and conditions have also been reported such as 
amount of asthma medication, comorbidities including obesity, occupational stress [31], 
sensitization, indoor and outdoor pollution, small airway dysfunction [32], loss of lung elastic 
recoil [33],  and psychological factors [29, 34–44]. Retrospective studies have shown  that 
repeated assessment of composite scores of control such as the Asthma Control Test (ACT) 
or Asthma Control Questionnaire (ACQ) and other tools, such as eHealth and mHealth[45], 
may predict severe exacerbations [46]. However, whether self-monitoring of asthma control 
score questionnaires at home can be useful to predict (and consequently, help to prevent) 
exacerbations in a real life setting needs to be further investigated [47–49]. An index of 
fluctuation of Peak Expiratory Flow (PEF) measurements at home was able to predict 
exacerbations [50]. Lastly, although a hospital admission provides proof of a severe 
exacerbation (see definition), the decision to hospitalize a patient with asthma also depends 
on the clinical course during management at the emergency department [2, 51, 52], and on 
additional factors such as age, inflammatory phenotype, presence of comorbidities [53, 54], 
and familial and social conditions [2, 51, 52]. 
 
3B. Modifiable vs non-modifiable factors and mathematical models 
Until recently, modifiable risk factors for exacerbations were mostly seen as behavioral 
issues or environmental triggers [55–58]. This included patients‟ beliefs (or parents‟ beliefs 
in the case of children) and expectations, poor inhalation technique and/or treatment 
adherence, (active or passive) smoking and allergen exposure (such as in-house pets, for 
example). More recently, the key role of viruses has been acknowledged, and viral triggers 
are now perceived as potentially modifiable factors. However, no therapeutic strategies have 
yet been able to successfully interfere with rhinovirus carriage and bouts of infections in 
children and adults; this is an important area of ongoing research. Accordingly, viral infection 
and  impaired host responses to rhinovirus can be modelled to predict the potential of new 
antiviral drugs [53, 59–61]. The synergistic action of allergen exposure (e.g. seasonal pollens, 
house dust mite) and viruses may indicate a place for combining strategies targeting each 
factor alone or in association [38, 55, 62]. 
 
High blood eosinophil count, reflecting type 2 (T2) inflammation, is well-recognized as a 
significant risk factor for asthma exacerbations [63], with a consistent dose-ranging effect 
reproduced in different large scale studies [64, 65]. The relative weight of elevated blood 
eosinophilia with any other predictor of future exacerbation is largely unknown, but is 
influenced by the level of asthma control, asthma severity, asthma phenotype (e.g. age at 
onset of asthma), lung function and history of exacerbations.  Validated biomarkers reflecting 
non-T2 asthma phenotype(s) remain an urgent unmet need [66]. The recognition of T2-related 
traits makes a patient with uncontrolled severe asthma eligible for biologic therapies targeting  
key T2 disease-drivers, such as eosinophils, IL-4, IL-13 and/or IgE [67]. Elevated blood 
eosinophil count is associated with an increased exacerbation risk and to date this is the most 
relevant phenotyping marker. The reduction in exacerbation rates provided by anti IgE-, -
TSLP, -IL-5- and -IL-4/IL-13 antibody therapy supports the concept that T2-associated 
asthma is associated with an increased risk of exacerbations [68, 69], even though it is not the 
only one. 
Asthma patients may follow many different trajectories [56]. These trajectories can be 
described under three main categories and sustain the concept of asthma severity (persistently 
severe, intermittently severe, never severe). Presently, exacerbations represent one of the key 
outcomes in asthma with the greatest asthma-related risks as defined by GINA [1] and hence, 
the development of innovative drugs and effective treatment modalities remains a priority. 
Exacerbations are episodes of acute respiratory distress; a situation that causes major stress 
for the patient themselves, their relatives and even for the health care providers. They 
represent an important economic burden both in terms of health care use and professional 
absenteeism. They are also associated with long term risks (relapses, side effects of 
treatments dominated by systemic steroids, lung function decline) [1, 9, 70]. Some single 
nucleotide polymorphisms (SNPs) and other gene modifiers summarized in Figure 1 could 
be associated with such long term risks [62, 71–82]. It appears worthwhile exploring the 
epigenetic modifications in well-characterized asthma populations, particularly in late onset 
disease. 
 
 
Figure 1 Potential severe asthma trajectories and the importance of risk factors and genetic variants (such as single 
nucleotide polymorphisms [SNPs]). this figure presents a summary of the literature and is not intended to be exhaustive 
 
3C. Risk factors and epidemiology, pheno/geno/endotypes. 
Since severity of asthma is presently defined by treatment requirement, which partly relies on 
previous exacerbation rates [3], the frequency of exacerbations is associated with severity. 
However, exacerbations are not restricted to patients with the severe form of asthma. 
Near-fatal asthma episodes can occur in patients even with so called “mild asthma”, 
implicating that “mild asthma (GINA step 1 and 2) “does not necessarily mean “low risk 
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asthma”. Most of the time, these patients are not receiving any anti-inflammatory treatment at 
the time of the event and their asthma can be well-controlled when it is correctly managed 
and treated [2, 35]. Near-fatal episodes represent a minority of exacerbations seen in the 
emergency department [2]. Interestingly, a hyperbolic curve relating inhaled corticosteroid 
(ICS) prescription refilling and asthma mortality is highly suggestive of a strong death-
preventing effect of ICS use [83]. Actually, asthma deaths due to exacerbations have 
decreased over time in westernized countries.  However, their incidence was still estimated to 
be more than 900 in the UK in the latest National Review of Asthma Deaths, and at least half 
of these dramatic cases were considered preventable [6, 84].  
Risk factors and clinical characteristics could be identified and robustly confirmed in 
different countries. These criteria should be known to all health care providers involved in the 
management of asthma and are shown in Table 2. 
Better characterization of disease mechanisms is required in those patients with an 
incomplete response to ICS (across GINA steps) [70]. Defining clinical phenotypes and 
mechanistic endotypes is a useful concept which has been developed to better manage these 
patients [85]. In the SARP-3 cohorts, five factors were positively associated with exacerbation 
frequency: chronic sinusitis, gastro-esophageal reflux, blood eosinophils, body mass index, 
and bronchodilator responsiveness. Clusters in primary care identified early onset and obesity 
as risk factors for exacerbations. A cluster of obese female asthmatics with recurrent 
exacerbations has been described in both SARP and UBIOPRED cohorts [86, 87]. 
Furthermore, a large scale study on children confirmed that obesity is linked with a shorter 
period of time between exacerbations [88]. Symptoms such as cough and wheeze are 
correlated with uncontrolled asthma, but are poorly associated with exacerbations [89]. 
Interestingly, new inflammatory patterns of exacerbations are currently described with the 
integration of the microbiome and T1-related cytokines [90]. A gene signature derived from 
sputum gene transcriptomics containing Charcot-Leyden crystal galectin [CLC]; 
carboxypeptidase 3 [CPA3]; deoxyribonuclease 1-like 3 [DNASE1L3]; alkaline phosphatase, 
liver/bone/kidney [ALPL]; CXCR2; and IL1β (a mixture of eosinophil and mast cell product 
with neutrophil-associated cytokines) can predict future exacerbation phenotypes of asthma, 
with the greatest biomarker performance compared to fractional exhaled nitric oxide values 
and sputum eosinophil counts in identifying those who would experience frequent severe 
exacerbations [91]. 
It should be kept in mind that very high blood eosinophil counts (e.g. more than a  thousand 
per mm3) are sometimes associated with other conditions such as eosinophilic granulomatous 
with polyangiitis (EGPA) or allergic bronchopulmonary aspergillosis (ABPA) which overlap 
with severe asthma. These specific conditions are prone to very frequent exacerbations. They 
are sometimes difficult to discriminate from severe asthma when all the diagnostic criteria are 
not fulfilled [92]. 
Table 2. Risk factors for various outcomes in asthma exacerbations 
 Likely Possible Ref 
RF for dying 
 
 B2 agonist overuse 
 No ICS treatment 
 Age 
 Virus infection 
 Gender 
 Drug and venom allergy 
 Allergen exposure (including 
thunderstorm asthma) 
 Intubation outside PICU 
 High number of ED visit 
 Sports 
 Alternaria and 
penicillium spores 
 Nitrogen dioxide, ozone 
 Severe asthma 
[35, 
93–
97] 
 
RF for ICU 
admission – 
near fatal 
asthma 
 
 No ICS treatment 
 Severe asthma 
 Virus infection 
 Loss of elastic recoil 
 Permanent airflow limitation 
 Hyperinflation 
 Menstruation 
 Steroid dependence 
 History of intubation 
 Delayed systemic 
corticosteroid use 
 Heroin, cocaine 
 
[33, 
39, 
41, 
98, 
99] 
RF for severe 
exacerbation – 
ED – admission 
 
 No ICS treatment 
 Comorbidities 
 Psychological issues 
 Age 
 Absence of ICS 
 Virus infection 
  
RF for frequent 
severe 
exacerbations 
(≥ 2 - 3 OCS 
bursts/y) 
 
 No ICS treatment 
 Virus infection 
 High blood eosinophil count 
 Smoking 
 Genetic 
 Atopy 
 BMI 
 BD responsiveness 
 Chronic sinusitis 
 Low socioeconomic 
status 
 GERD 
 Aspirin sensitive 
 Climate- Thunderstorms 
during pollen season 
[54, 
100, 
101] 
RF = risk factor; BD = bronchodilator; BMI = body mass index; ED= emergency department; 
ICS = inhaled corticosteroids; ICU= intensive care unit; GERD = gastro-esophageal reflux 
disease; NFA= near-fatal asthma attack; OCS = oral corticosteroids 
 
  
3D. Typology– gender, psychosocial factors. Perception, Compliance/Adherence  
Poor treatment adherence is a major trigger for loss of control at the population level, and this 
is a common finding also for onset of exacerbations [102]. Although ICS treatment is able to 
decrease the exacerbation rate at all dose ranges [103], it seems that an adherence of at least 
75% of the prescribed dose (hazard ratio [HR] 0.61; 95% confidence interval [CI] 0.41–0.90) 
is required to achieve this goal [103]. Of note, 24% of exacerbations can be attributed to poor 
adherence, which is often unintentional due to poor inhalation technique. Moreover, running 
out of inhaler was frequently reported in ED-attending asthmatics [104]. The use of multiple 
devices, especially when different principles are mixed, such as dry powder inhalers and 
metered dose inhalers (MDI), is also a risk [105]. Non-consented switching of inhalers has 
also been shown to be a significant risk factor for exacerbation; these apparent cost-sparing 
measures in the short-term are thus  subsequently countered by increased health care 
utilization [106]. Alexithymia [107] , specific personality traits [108],  and poor perception of 
symptoms may lead to a delayed request for help [95–100]. Female gender [109, 110], 
ethnicity [111, 112] and patient beliefs [113]could also be identified as risk factors for 
exacerbation. The prevalence of psychological dysfunction, including anxiety and depression, 
is increased in patients with asthma and has been shown to be related to severity of the 
disease [114]. Anxiety and depression are also strong predictors for poor asthma control [115]. 
Poor adherence is well documented for ICS; but new injectable biologics also appear 
susceptible to this, particularly when self-administered [116]. On the other hand, self-
administration is likely to improve access to treatment and to reduce the burden of the disease 
[117]. 
Several drawbacks could be raised against therapeutic educational programs, but at present 
many simple and efficient solutions extensively reviewed elsewhere can work [70, 102]. The 
benefits of written or web-based action plans are worth investigations [118]. Furthermore, 
e-Health solutions such as electronic reminder messages and, more recently, connected (to a 
computer or a smartphone) inhaler devices can be implemented and have been shown to be 
effective [119, 120], but as they are usually only geared towards the use of one single inhaler 
per patient and no other medication it is likely of limited value for patients requiring multiple 
medications. However, these interventions should be prospectively evaluated for their ability 
to decrease exacerbation rates over time and whether they are really easing patients‟ lives. 
Stronger partnerships between patients and health care professionals are likely to improve 
adherence and new self-adherence programs should be developed and tested for their effect 
on preventing (severe) exacerbations. 
Although there is no perfect tool for associating a severe asthma exacerbation with poor 
adherence, a minimal adherence checklist is proposed in GINA and the task force decided to 
echo it presently (Table 3). Dose-counter displaying devices are preferred options according 
to a European Lung Foundation (ELF) open discussion organized for the present task force. 
  
 
Factors contributing to poor adherence 
Medication/Regimen factors 
- Difficulties using inhaler device 
- Burdensome regimen (e.g. multiple times per day) 
- Multiple different inhalers 
Unintentional poor adherence 
- Misunderstanding about instructions 
- Forgetfulness 
- Absence of a daily routine 
- Cost 
Intentional poor adherence 
- Perception that treatment is not necessary 
- Denial or anger about asthma or its treatment 
- Inappropriate expectations 
- Concerns about side-effects (real or perceived) 
- Dissatisfaction with health care providers 
- Stigmatization 
- Cultural or religious issues 
- Cost 
How to identify poor adherence in clinical practice 
Ask an empathic question 
- Acknowledge the likelihood of incomplete adherence and encourage an open non-judgmental discussion 
Check medication usage 
- Check the date of the last controller prescription 
- Check the date and dose counter on the inhaler 
- In some health systems, prescribing and dispensing frequency can be monitored electronically by clinicians 
and/or pharmacists 
Examples of successful adherence interventions 
- Shared decision-making for medication/dose choice 
- Inhaler reminders for missed doses 
- Prescribing ICS once-daily versus twice-daily 
- Home visits for a comprehensive asthma program by an asthma nurse 
Table 3. Factors affecting adherence in clinical practice, according to GINA [1]. 
  
  
 
3E. Virus/allergens 
A synergy exists between respiratory viral infections and allergen exposure inducing asthma 
and causing exacerbations in susceptible, sensitized asthmatics [38, 55, 62]. Additionally, 
interaction between lower respiratory tract viral infections (LRTI) and atopic sensitization 
has been recognized as a major risk factor contributing to asthma development and 
exacerbations [62, 121]. Birth cohort studies provide strong evidence for a synergistic effect 
of viral LRTIs and atopic sensitization on risk of asthma inception, particularly in 
predisposed children [122, 123]. Several studies in both sensitized children [55, 124] and adults 
[16, 38] found a strong association between the levels of specific IgE to inhaled allergens and 
viral LRTIs in increasing the risk of severe asthma exacerbations requiring hospital 
admission. 
The synergism between allergen sensitization and viral LRTIs has been indirectly confirmed 
in a study in asthmatic children, showing that pretreatment with omalizumab decreases 
asthma exacerbations in fall, which are likely (rhino-)virus-induced [125]. Recent evidence 
demonstrates that omalizumab restores deficient anti-viral immunity in children with asthma, 
and that exacerbation reduction with omalizumab was greatest in those with greatest 
restoration of anti-viral immunity [125]. Rhinoviruses (RV), especially RV-A and RV-C 
groups, are the most frequent viruses detected during an asthma exacerbation including 
severe asthma exacerbations with near-fatal and fatal asthma, and allergic asthmatics usually 
experience more severe and prolonged LRTI symptoms with RV infection compared to non-
atopic healthy controls [38, 55, 126]. Interestingly, CDHR3 polymorphism is a risk factor for 
RV induced severe asthma exacerbations in children [71], possibly because it has recently 
been shown to be an RV-C receptor [127]. Another study showed that documenting a viral 
infection in the ED was a strong predictor for ED re-attendance in children [128]. Impaired 
interferon responses to RV infection are associated with asthma in both adults and children 
[105, 106], and are associated with increased RV-induced asthma exacerbation severity [131] 
Although appealing, the development of a RV vaccine appears highly challenging 
[132]However, a proof of concept study on inhaled IFN-β as a therapeutic intervention in 
virus-induced asthma exacerbations only showed benefit in a subgroup of people with 
moderate/severe asthma [133], implicating that further research is needed  to investigate the 
concept of interferon supplementation in asthmatics at exacerbation onset. 
 
3F. Environmental factors: indoor/outdoor air pollution & occupational factors 
Outdoor air pollution is an established risk factor for asthma exacerbations, although the 
magnitude of effect remains difficult to assess precisely [101]. Diesel exhaust particles and 
peaks of ambient air pollution, (reflected by, amongst others, high levels of nitrogen dioxide 
and ozone) were shown as concomitant factors to emergency department attendance in 
asthmatics but also could be epidemiologically related to asthma exacerbations and deaths 
[97]. Work-related exacerbations are probably underestimated whereas many different non-
specific irritants could be identified such as mineral dusts, gas and fumes etc. [134].  
Indoor air pollution comprises second-hand tobacco smoke exposure, which is of special 
interest in children, but also other less well-known contributors such as volatile organic 
compounds (VOC) [135]. Open fire place, sick building syndrome, cleaning supplies and 
household products, and inadequate ventilation are also to be integrated into potential sources 
of indoor air pollution. We propose to test whether facilitating access to air quality data 
records may prevent asthma exacerbations. The European Lung Foundation (ELF), while 
reviewing the present manuscript, supports the use of portable air quality sensors, but more 
research is needed to know what and how to measure the right substances. 
Occupational sensitizers and triggers have been cause for concern for many years and efforts 
have been taken to limit their impact. All TF members in their practice consider it worthwhile 
facilitating access to free and independent experts in occupational medicine, as well as using 
FENO, spirometry, and potentially other relevant diagnostic tests (e.g. induced sputum) at 
work, especially considering their relatively low direct and indirect costs. More research is 
needed on occupational triggers and their effect on severe asthma exacerbations. Patients also 
raised the need to support asthma patients when choosing careers to avoid known and 
dangerous sensitizers and triggers. 
 
3G. Drugs & irritants / Excessive use of 2-agonists 
Whether drugs known to affect airway smooth muscle tone (such as -blockers) are able to 
trigger an asthma exacerbation is unclear. Non-steroidal anti-inflammatory drugs (NSAID) 
and aspirin intake in susceptible patients induces asthma exacerbations, and low dose 
induction of tolerance must be investigated to assess their benefit in preventing 
exacerbations. 
Excessive use of short-acting 2-agonists (SABA) in the absence of ICS use has long been 
linked to hospitalizations and asthma deaths, best exemplified by asthma deaths epidemics 
related to high doses of fenoterol reported in New Zealand and other countries [136]. Also 
regular use of long-acting 2-agonists (LABA) in the absence of ICS has been shown to 
increase significantly the risk of asthma exacerbations and asthma deaths potentially through 
a “masking” effect [137–139]. Not only overuse, but also regular use of SABA – without ICS 
[140] – has also been associated with paradoxical asthma worsening [52, 141]. Mechanisms 
involved are not fully understood, but may relate to induction of inflammatory mediators in 
bronchial epithelial cells by 2-agonists (both SABA and LABA), when administered in the 
absence of ICS [142] , and/or by a tachyphylaxis phenomenon but this is still to be 
demonstrated in vivo [143]. Because several short and long acting 2-agonists are now 
available, their potential side effects should be assessed in detail and reported, especially as 
paradoxical triggers for loss of control and exacerbations. The TF members limit these issues 
by systematic concomitant ICS use and reassess the patients repeatedly. Most TF members 
avoid frequent and inappropriate use of repeated or regular high doses of SABA irrespective 
of the manner of administration (inhaled: pMDI, DPI, or nebulisation) without medical 
supervision. 
  
 
4. ACUTE MANAGEMENT 
TREATMENT OF SEVERE ASTHMA EXACERBATIONS 
Despite optimum maintenance therapy and appropriate prevention strategies, severe 
exacerbations occur, even in patients with mild disease or well-controlled asthma [1, 144]. 
Therefore, proper assessment and adequate intervention are crucial to stabilize asthma and 
alleviate symptoms. Although in recent years there has been ample research into the 
treatment of stable asthma and several new drugs and formulations have been marketed, so 
far a limited number of treatments are available for asthma exacerbations while limited 
evidence exists in support of their use [145]. 
For patients presenting with acute asthma to primary care or emergency department (ED), the 
TF members consider that a proper assessment of exacerbation severity is determined based 
on history, physical examination and objective measurements of lung function and oxygen 
saturation [146] (Figure 2). Arterial blood gas measurements and chest X-ray are not 
included in the guidelines dedicated to the initial assessment, nevertheless they are performed 
by all the TF members for patients with severe exacerbations and for those who do not 
respond to initial treatment or are deteriorating [147–149].  
Information from patients‟ history can identify those who are at increased risk of worst 
outcome and asthma-related death and prompt arrangements to be made for more frequent 
evaluation and aggressive treatment (Table 2). 
Treatment is usually started immediately and simultaneously with the initial evaluation of the 
patient. The following treatments are usually administered concurrently to achieve the most 
rapid resolution of the exacerbation and prevent patient deterioration. 
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Figure 2: Assessment of exacerbation severity based physical signs and objective measurements (adapted from GINA [1]) 
 
 
 
 
 
 
 
 
 
 
 
Oxygen 
Oxygen is usually delivered by nasal cannula or Venturi mask in order to achieve arterial 
oxygen saturation of 93–98%. In severe exacerbations, high concentration oxygen increases 
the risk of hypercapnia while controlled low flow oxygen therapy is associated with better 
outcomes [150–152]. 
 
Short-acting 2-agonists (SABA) 
SABAs intend to resolve bronchospasm and to relieve acute symptoms of asthma, and are 
usually initially administered every 15 to 20 minutes for the first hour during an acute asthma 
exacerbation. Comparison of pMDI-spacer and nebulizer has shown increased efficiency of 
SABA delivery via pMDI-spacer and equivalent clinical outcomes [153, 154]. Data are 
conflicting whether continuous nebulization with a SABA is superior to intermittent 
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nebulization [155, 156]. In severe asthma exacerbations, continuous nebulization may be 
preferred, based on evidence of reduced admissions and improved pulmonary function [155, 
157]. There is no evidence to support the routine use of intravenous 2-agonists in patients 
with severe asthma exacerbations [158]. 
 
Ipratropium bromide 
Adding ipratropium bromide to SABA decreases rates of hospitalizations and shortens ED 
stays for patients with severe asthma exacerbations [159–161]. Some evidence shows that the 
use of combination ipratropium/-agonist therapy in acute asthmatic exacerbations provides 
benefit without increased risk of adverse events [161]. 
 
Corticosteroids 
Early administration of systemic corticosteroids for the treatment of asthma exacerbations is 
considered a standard of care and is recommended worldwide to be given to the patient 
within 1 hour of presentation [162, 163]. A systematic review showed that the use of systemic 
corticosteroids reduces the rate of hospital admission in ED settings, especially in patients 
with severe asthma and those not currently receiving corticosteroids [164]. 
The optimal dose for systemic corticosteroids in asthma exacerbations remains to be 
established. Doses above 2 mg/kg or 60-80 mg/day do not add benefit to improving lung 
function, rates of hospital admission or length of hospital stay [162, 165]. Furthermore, no 
differences are found between oral and intravenous administration of comparable 
corticosteroid doses [166, 167]. Thus, daily doses of OCS equivalent to 50 mg prednisolone as 
a single morning dose, or 200 mg hydrocortisone in divided doses, are adequate for most 
patients [1]. A short course of 5 days OCS after ED treatment of acute asthma exacerbations 
has been shown to reduce the rate of relapse [1, 164]. Courses longer than 5 days or a dose 
tapering did not provide additional benefit while increased side effects [168, 169].  
The role of ICS in the management of asthma in the emergency department remain unclear 
and their use in severe asthma exacerbations is not evenly adopted [170]. 
 
Other treatments 
None of the TF members use intravenous aminophylline and theophylline in the management 
of asthma exacerbations, in view of their poor efficacy and safety profile [1]. Intravenous 
magnesium sulphate (given as a single 2g infusion over 20 minutes) has been shown to 
reduce hospital admissions in severe exacerbations and in patients who fail to respond to 
initial treatment [171, 172]. Evidence does not support a role of antibiotics in asthma 
exacerbations unless there is strong presumption of lung infection [1, 173]. Other associated 
advices of management (hydration, physiotherapy, avoid exercise, etc.) are poorly evidenced 
[174]. Noteworthy, exercise outside an episode of exacerbation should be largely supported as 
it was shown to prevent exacerbations and to improve control [175]. 
 
  
5. PREVENTION 
Here we describe the evidence for current therapies available across the severity spectrum of 
asthma, licensed biologics and those in phase 3 clinical development.   
 
Current small molecule asthma therapies 
Corticosteroids 
Extensive data support the role of inhaled corticosteroids in asthma with increasing dose 
reducing exacerbation frequency [1, 176, 177]. Increasing the ICS dose four-fold at the onset 
of exacerbation symptoms reduced the need for systemic corticosteroids by 19% [178]. No 
randomized controlled trials exist of prednisolone versus placebo as add-on therapy in severe 
asthma [179]. Registry data suggested that maintenance oral corticosteroid use was associated 
with reduced exacerbations among a cohort of severe asthmatics [180]. In a small study, high-
dose intramuscular triamcinolone reduced hospital admissions and emergency department 
attendances; however, the long-term side effect profiles of systemic steroids have to be taken 
in mind. TF members use maintenance OCS as a therapeutic strategy for reducing 
exacerbations as a less preferred option and suggest this practice be supervised in expert 
referral centers familiar with the management and prevention of OCS side effects [181]. 
Presence of eosinophilic inflammation predicts a good response to corticosteroids in airways 
disease [182–184]. Tailoring corticosteroid dose to control sputum eosinophilia in asthma has 
achieved marked reductions in exacerbation rates [16, 18, 185] and the ERS/ATS guideline 
advocates measurement of eosinophilic inflammation in severe asthma [3]. 
Given the superiority of an on-demand ICS-containing regimen in two separate trials 
performed in patients with mild asthma in reducing the risk of exacerbation [186, 187], later 
confirmed in a real-life setting [188], the last GINA update promotes this strategy as early as 
step 1, acknowledging the obvious inflammatory nature of the disease and in particular 
during episodes of poor control that precedes exacerbation. 
The management of asthma using a sputum-guided adjustment of the daily dose of ICS was 
shown efficient to prevent exacerbations in expert centers where induced sputum cytology 
can be assessed routinely, in patients able to provide an adequate sample within the safety 
margins of induction [16, 18]. 
 
Long Acting Beta-Agonists (LABA) added to ICS 
ICS-LABA combination therapy is standard in severe asthma and the addition of a LABA to 
ICS reduces exacerbation frequency in asthma [1, 176, 177]. The TF echoed recurrent 
warnings regarding monotherapy with LABA in asthma [189]. 
 
Long Acting Muscarinic Antagonists (LAMA) added to ICS 
Tiotropium, as add-on therapy for asthmatics uncontrolled while treated with ICS and LABA, 
increased time to first exacerbation by 56 days versus placebo (P=0.03) [190]. A Cochrane 
review of LAMA added to ICS vs ICS alone across all severities of asthma showed a 
reduction in exacerbations requiring oral corticosteroids, and a trend towards reduction in 
hospital admissions [191]. 
 
Leukotriene Receptor Antagonists (LTRA) 
A systematic review of LTRAs identified a significant reduction in exacerbations when used 
as monotherapy compared to placebo, but no effect on exacerbation rates when used in 
patients already taking inhaled corticosteroids [192]. Whether LTRAs reduce severe 
exacerbations in severe asthmatics is unknown. 
 
Theophylline 
A study comparing ICS/LABA and theophylline vs ICS/LABA and placebo found a 
significant reduction in severe exacerbations in the theophylline group in asthmatics who 
were treatment naïve [193]. Whether theophylline affects exacerbation frequency in severe 
asthma is unknown. Most TF members do not use theophylline as an add-on therapy for 
preventing exacerbations. 
 
Antimicrobials 
In a large clinical trial thrice-weekly azithromycin in moderate-to-severe asthma resulted in a 
41% reduction in severe exacerbations with benefits independent of inflammatory phenotype 
[194], in contrast to a previous sub-analysis in severe asthmatic patients where the benefits 
were limited to the non-eosinophilic subgroup [195]. Of note, worldwide, azithromycin is not 
approved to the best of knowledge in this indication. Anti-fungal agents in fungal-sensitized 
severe asthma not meeting criteria for allergic bronchopulmonary aspergillosis demonstrated 
no impact on severe exacerbations [196]. 
 
Immunosuppressants 
Data reporting exacerbations was limited in a Cochrane review examining the corticosteroid 
sparing effect of cyclosporin in severe oral corticosteroid dependent asthma [197]. A similar 
review examining the corticosteroid sparing effects of methotrexate in severe asthma did not 
demonstrate a beneficial effect on exacerbation rates [198]. 
 
Allergen avoidance and immunotherapy 
Allergen avoidance advice is standard clinical practice in severe asthma [1, 176, 177], but 
allergen avoidance has shown controversial benefit [199] possibly due to difficulty in 
achieving this effectively. Allergen immunotherapy (AIT) strategies in asthma report some 
benefit for reducing symptoms and corticosteroid usage but have not been tested in severe 
asthma [200]. It is unknown whether measures such as nocturnal temperature controlled 
laminar flow will be effective. Reductions in airway inflammation are reported in atopic 
asthma [201] and studies in severe asthma are ongoing [202]. 
 
Current biologics for asthma (Table 4) 
The phase 3 RCTs for currently available biological therapy in asthma, except for anti-IgE as 
more established, are summarized in Table 4, including phase 2b studies that were considered 
pivotal for registration. Studies in less severe asthma with a very low event rate, open-label 
extensions that confirmed earlier findings and studies that did not report exacerbations were 
not included.        
 
Anti-IgE: Omalizumab 
A Cochrane review of omalizumab as add-on therapy in moderate-to-severe asthma reported 
a reduction (odds ratio (OR) 0.55, 95% confidence interval (CI) 0.42 to 0.60; ten studies, 
3261 participants) in severe exacerbations [203], however subgroup analysis of severe asthma 
alone did not demonstrate a clear benefit. Further clinical trials remain ongoing [201]. 
 
Anti-IL5: Mepolizumab and Reslizumab 
Mepolizumab reduces exacerbation frequency by ~50% [5, 65, 204–206] and reduces the 
requirement for maintenance oral corticosteroid [206]. Benefits were observed in severe 
asthmatics with blood eosinophils >150cells/µL [207], with greatest exacerbation frequency 
reductions seen with increasing eosinophilic inflammation. These beneficial effects were not 
sustained over the 12 months following treatment withdrawal [208] while it was the case 
when treatment was maintained [209]. This exacerbation rate reduction was also achieved 
while tapering OCS in long term OCS users[210]. Reslizumab demonstrated a reduction in 
severe exacerbations in severe asthmatics with a baseline blood eosinophil count >400 
cells/µL [211]. Improvements were greatest in those with GINA step 5 disease [212]. 
 
Anti-IL5R: Benralizumab 
Benralizumab reduces severe exacerbations [64, 213, 214] in those with a blood eosinophil 
count >300 cells/µL. A priori sub-analyses using an eosinophil cut off of 150 cells/µL also 
demonstrated significant reductions in exacerbation rates [215], although higher blood 
eosinophils and more frequent exacerbations predicted greater benefits [216]. This 
exacerbation rate reduction was also achieved while tapering OCS in long term OCS users 
[214]. A study of benralizumab administered in the setting of acute asthma exacerbation [66] 
reported a positive impact on recovery rates, however further work would be required to 
define the use of biologics in this setting. 
 
Bronchial Thermoplasty 
In 190 subjects who received bronchial thermoplasty (BT) versus 98 who underwent sham 
procedures severe exacerbations were reduced by 32% in the 3-12 months post therapy with 
an increase in exacerbation events in the peri-procedure period [21]. This reduction in 
exacerbations was maintained over a 5 year follow up period [217]. BT is currently performed 
only in trained centers for both managing severe asthma and handling BT. 
 
Emerging biologics 
Anti-IL4R: Dupilumab 
Dupilumab reduced severe exacerbations in all-comers irrespectively of the atopic status, 
with the greatest reduction in those with elevated FeNO and/or eosinophilic inflammation, 
and reduced oral corticosteroid requirement for severe asthmatics receiving maintenance oral 
corticosteroids [68, 218, 219]. Studies of IL4 inhibition alone and more recently of the anti-
IL13 biologics lebrikizumab [220] and tralokinumab [221] have failed to meet their primary 
endpoints of exacerbation reduction, suggesting that inhibition of both IL-4 and 13, as with 
anti-IL4R, is necessary to observe sufficient clinical efficacy for this aspect of the disease. 
 
Anti-TSLP: Tezepelumab 
A recent phase II trial investigated the impact of tezepelumab on exacerbation rates in 584 
moderate-to-severe asthmatics, showing a 60-70% reduction in exacerbations in all-comers 
across dosing regimens [222]. Effects were observed irrespective of markers of T2 
inflammation, although substantial reductions in these measures were noted, suggesting that 
targeting upstream cytokine pathways may reduce exacerbations across inflammatory 
profiles. 
 
CRTH2 antagonists, anti IL17 and others 
ILC2 are now seen as the pivotal cells ofT2 airway inflammation. Because they specifically 
express the PGD2 receptor DP2 or CRTH2, a proof of concept study showed that anti-DP2 
treatment could significantly reduce the blood eosinophil count [223]. Whether this will be 
sufficient for preventing exacerbations is the aim of a larger ongoing phase III trial. 
 
The IL33-ST2 axis is also specifically targeting ILC2 [224] and pivotal studies are ongoing. 
In non T2 asthma, the relevance of blocking IL17 for preventing exacerbations is also 
currently being tested [225]. 
 
Conclusion 
Reduction and ultimately elimination of severe exacerbations in severe asthma remains an 
important therapeutic target. In addition to corticosteroids and allergen 
avoidance/immunotherapy, the biologics targeting T2-immunity and eosinophilic 
inflammation (anti-IgE, IL-5, IL-4R and TSLP) reduce exacerbations. Whether other 
therapies that reduce eosinophilic inflammation such as anti-DP2, will demonstrate a similar 
efficacy remains to be determined. Beyond T2 inflammation, macrolide antibiotics and 
bronchial thermoplasty may have a role, but reducing severe exacerbations in non-T2 severe 
asthma remains an unmet need, although the scale of its importance once T2-mediated 
disease is adequately treated is uncertain. 
 
5. CONCLUSION AND BULLET POINTS FROM THE ELF 
Preventing severe exacerbations in asthma is very important from the perspective of people 
with asthma. Too many patients still die, whereas these deaths are likely preventable, from a 
severe exacerbation. In some countries asthma and respiratory deaths are still increasing, 
especially in non-severe and moderate asthma [84]. Why this is happening still needs to be 
explored but facilitating access to care and medications would probably be efficient. 
 In all types of asthma: It is important to remain aware that severe exacerbations don‟t 
just happen in patients with the more severe types of asthma. 
 Exacerbations and especially recurrent exacerbations are very debilitating for patients. 
More research is needed to avoid exacerbations and to break the cycle of recurrent 
exacerbations. The medications and treatments plans that are available at this time do 
not seem to be working well enough for all patients. 
 Adherence: patients and physicians need to work together on improving adherence. 
Good communication between physician and patient is key. There are many factors 
that impede adherence for patients. Some straight-forward ways to support patients 
can be implemented easily like having dose-counters on all inhalators. It can be more 
challenging to address patients developing additional behavior. All aspects require 
continuous positive attention from physicians.  
 Indoor and outdoor environmental factors: the advice to avoid environmental factors 
is an additional burden moreover because it is extremely complex to put into practice 
for patients. More and better advice needs to be given to patients on living conditions, 
occupational choices etc.  
 Working together with patients in improving their asthma care is key. Many patients 
have good knowledge on their asthma and their reaction to medications. Not all 
patients have this insight and not all patients are able to manage their asthma on a 
daily basis. We all need personalized help. E-health can support some patients, but 
only if these solutions are developed with patients and are sufficiently flexible and 
personalized. 
Research needs and knowledge caps identified throughout this task force are summarized 
table 5. 
 
  
Table 4: Pivotal Phase 3 randomised clinical trials of licensed biologics (excluding anti-IgE)   
Interventio
n 
Reference Population Description of 
intervention/ 
duration 
Effect on exacerbations 
Mepolizu
mab 
Anti-IL5 
 
MUSCA 
[205] 
 
Adults and children (>12 years), n = 556 
≥2 exacerbations in last year 
Blood eosinophils ≥300/µl in last 12 months 
or ≥150/µl at screening 
100mg SC 
Q4W 
24 weeks 
↓ exacerbation rate 42%  
↓ exacerbations requiring emergency department (ED) 
visit or hospitalization 32% 
No significant change in hospitalizations alone 
SIRIUS 
[226] 
Adults (16 – 74 years), n = 135 
Background therapy 5 to 35 mg/day of 
prednisone or its equivalent for > 6 months 
Blood eosinophil count ≥150 cells/µL at 
screening or ≥300 cells/µL in the last year 
100mg SC 
Q4W 
20 weeks 
↓ exacerbation rate 32%  
OR for glucocorticoid reduction 2.39 in mepolizumab 
group (0.008) 
Median glucocorticoid reduction 50% (vs 0% in controls) 
 
 
MENSA 
[5] 
Adults and children (aged ≥12 years), n = 576 
≥2 exacerbations in last year 
Blood eosinophil count ≥150 cells/µL at 
screening or ≥300 cells/µL in the last year 
75mg IV 
Q4W or 
100mg SC 
Q4W  
32 weeks 
↓ exacerbation rate 47 - 53%  
SC mepolizumab ↓ exacerbations requiring 
ED/hospitalization (61%) and exacerbations requiring 
hospitalization (69%) 
↓ systemic glucocorticoid exposure 41%  
Pavord 
Lancet 
2012 [53] 
(Phase 
2b/3) 
Adults and children (12 – 74 years), n = 621 
≥2 exacerbations in last year 
Sputum eosinophils ≥ 3%, FeNO ≥ 50 ppb, 
blood eosinophil count ≥ 300 cells/µL or 
deterioration in asthma control with ≤ 25% 
reduction in corticosteroid treatment (in the 
last year) 
75mg IV 
Q4W or 
250mg IV 
Q4W or 
750mg IV 
Q4W 
52 weeks 
↓ exacerbations 39 - 52% 
Exacerbations requiring ED/hospitalization reduced across 
all groups  
Greatest reduction in exacerbations with baseline 
eosinophils > 500 cells/µL 
Reslizuma
b 
Anti-IL-5 
Castro 
[211] 
Adults and children (12 – 75 years), n = 953 
(study 1 n=489, study 2 n=464) 
≥1 exacerbation in last year 
Blood eosinophil count ≥400 cells/µL 
3mg/kg IV 
Q4W 
52 weeks 
↓ exacerbation rate 54%  
↓ exacerbations requiring OCS 57%  
↓ exacerbations in those on OCS at baseline by 68%  
Exacerbations ↓ 64% if ≥4 exacerbations in last 12 months 
at baseline (vs. ↓ 32% if 1 exacerbation last 12 months)  
Benralizu
mab 
Anti-IL-
5R 
 
ZONDA 
[214] 
Adults (18 – 75 years), n = 220 
Background therapy (7.5 – 40mg/day 
prednisolone or its equivalent for > 6 months) 
Blood eosinophils ≥150 cells/µL at screening 
30mg SC 
Q4W or Q8W 
28 weeks 
↓ exacerbation rate 55 - 70% Q8W 
Q8W dosing reduced exacerbations associated with ED 
visit or hospitalization by 93%  
OR for glucocorticoid reduction  4.1 
Median glucocorticoid reduction 75% (vs 25% in controls) 
SIROCCO 
[64] 
Adults and children (12 – 75 years), n = 1205 
≥2 exacerbations in last year 
 
30mg SC 
Q4W or Q8W 
48 weeks 
Eosinophil High (≥300 cells per µL): 
↓ exacerbations 45 - 51%    
Q8W dosing reduced exacerbations associated with ED 
visit or hospitalization by 68% 
CALIMA 
[213] 
As per SIROCCO, n = 306 30mg SC 
Q4W or Q8W 
Eosinophil High  
↓ exacerbations 28 - 36%  
56 weeks No effect on hospitalizations/ED visits 
Dupiluma
b 
Anti-
IL4Rα 
 
Castro 
NEJM 
2018 
QUEST 
[68] 
Adults and children (≥12 years), n = 1902 
≥ 1 exacerbation in last year 
 
200mg SC 
Q2W or 
300mg SC 
Q2W 
52 weeks 
↓ severe exacerbations 46% across treatment population  
≥150 eosinophils/µL: ↓ exacerbations 60%  
≥300 eosinophils/µL: ↓ exacerbations 67%  
 
VENTUR
E [69] 
Adults and children (≥12 years), n = 210 
Background therapy (5 – 35mg/day 
prednisolone or equivalent for > 6 months) 
300mg SC 
Q2W 
24 weeks 
↓ severe exacerbations 59% across treatment populations   
≥150 eosinophils/µL: ↓ exacerbations 58%  
≥300 eosinophils/µL: ↓ exacerbations 71% 
Median glucocorticoid reduction 100% (vs 50% in 
controls) 
 
Table 5. Research needs and knowledge gaps 
Item Research   needs Type of study design Type of outcomes that need 
to be assessed 
Definition of 
severe 
exacerbation 
To assess in routine practice 
what is the most sensitive and 
specific definition (duration of 
OCS requirement, daily dose 
and cumulative dose) 
Re-analysis of RCT and 
real-life trials where diaries 
and home monitoring were 
used 
Registries and cohorts 
Rates of OCS bursts ≥ 5d, 
ED, admissions, need for 
ICU 
Definition of 
severe 
exacerbation 
To assess prediction models 
in real life cohorts 
Re-analysis of RCT and 
real-life trials where diaries 
and home monitoring were 
used 
Registries and cohorts 
Rates of OCS bursts ≥ 5d, 
ED, admissions, need for 
ICU 
Definition of 
severe 
exacerbation 
To establish composite scores 
to assess immediate risk 
Retrospective analysis of 
databases of exacerbations 
Short term outcomes: 
admission, ICU, intubation, 
deaths, treatment related 
adverse events 
Strategy To assess the impact of self-
monitoring on asthma control 
and prevention of 
exacerbations 
Randomised controlled trials 
comparing conventional vs 
self-monitoring strategy 
Rates of OCS bursts ≥ 5d, 
ED, admissions, need for 
ICU 
Strategy To assess the effectiveness of 
interventions to prevent 
human rhinovirus carriage 
Randomised controlled trials 
comparing strategies 
Rates of OCS bursts ≥ 5d, 
ED, admissions, need for 
ICU 
Risk 
factor/trigger 
To assess the weight of blood 
eosinophilia compared to other 
risk factors at the individual 
level 
Prospective cohort studies 
integrating all risk factors 
Rates of OCS bursts ≥ 5d, 
ED, admissions, need for 
ICU 
Risk 
factor/trigger 
To assess the benefits and 
risks of genetic analysis 
awareness at the individual 
level to predict severe 
exacerbation and asthma 
trajectory 
Test acceptability 
RCT comparing strategies of 
management in patients with 
known at-risk allele carriage 
vs routine 
Severe exacerbation rates 
in patients and relatives, in 
particular in children with 
high risk scores (familial 
risk, patients already 
admitted in ICU) 
Risk 
factor/trigger 
To more accurately know the 
mechanisms, rate and risk 
factors of deaths attributable 
Multiple exhaustive reviews 
of asthma deaths. 
Worldwide collection of 
Biology, pathology 
 
to severe exacerbations that 
occurred despite an optimal 
preventive strategy and acute 
management 
cases where death occurred 
despite optimal 
management 
Risk 
factor/trigger 
To identify and weight all risk 
factors associated with death, 
ICU, ED and frequent 
exacerbations 
Cohorts and registries of 
compelling cases 
Rates of OCS bursts ≥ 5d, 
ED, admissions, need for 
ICU 
Risk 
factor/trigger 
To identify tools for 
assessing/improving 
adherence 
RCT comparing strategies Rates of OCS bursts ≥ 5d, 
ED, admissions, need for 
ICU 
Risk 
factor/trigger 
To assess the benefits of 
eHealth-connected devices to 
prevent severe exacerbation 
RCT comparing strategies Rates of OCS bursts ≥ 5d, 
ED, admissions, need for 
ICU 
Risk 
factor/trigger 
to assess tools / resources / 
methods (e.g. shared decision 
making, systematic 
multidisciplinary approaches, 
referral to asthma centres) to 
improve patient-HCP 
partnership 
Studies assessing changes 
in patient-HCP partnership 
through training, education 
programs, etc.  
Parallel studies associating 
changes in patient-HCP 
partnership with changes in 
severe exacerbation rates 
Risk 
factor/trigger 
To assess the benefits of 
using air quality sensors 
RCT in selected populations Rates of OCS bursts ≥ 5d, 
ED, admissions, need for 
ICU 
Risk 
factor/trigger 
To assess the benefits of more 
accurately evidence the role of 
occupational triggers 
Basic science, models, 
psycho and sociology 
Rooms of exposition with 
inflammatory / lung function 
monitoring 
HRQOL 
Risk 
factor/trigger 
To assess the preventive 
benefits of convincingly 
support patient when choosing 
careers 
Prospective cohorts with 
randomized strategies 
In teenagers/young adults 
and in people changing of 
occupation 
Risk 
factor/trigger 
To assess the exact role of 
drugs in severe 
exacerbations.(incidence, 
dose, diagnosis, prevention)  
Prospective cohorts with 
randomized strategies. 
Models of exposition in 
animals and cell models 
Prospective recording of 
severe exacerbation. 
Maximal documentation of 
each event. 
Treatment of To define the value of CXR Randomized controlled trials Dedicated populations such 
 
severe 
exacerbation 
and arterial blood gases in 
acute management 
as ED attending 
Treatment of 
severe 
exacerbation 
To establish an optimal 
scheme for SABA 
administration 
Randomized controlled trials 
comparing different 
strategies of SABA 
administration (dose, route, 
frequency, duration, 
associated treatment) 
Rates of OCS bursts ≥ 5d, 
ED discharge vs 
admissions, need for ICU, 
adverse events 
Treatment of 
severe 
exacerbation 
To assess the role of ICS 
during the exacerbation and at 
discharge 
Randomized controlled trials Rates of relapses, spred of 
recovery, adverse events 
Treatment of 
severe 
exacerbation 
To assess  the benefits of 
hydration, physiotherapy, 
exercise avoidance during 
exacerbation; optimal time to 
go back to exercise 
Randomized controlled 
trials, comparative studies 
Rates of relapses, speed of 
recovery, adverse events, 
quality of life 
Prevention To assess whether LTRAs 
add-on reduce severe 
exacerbations in severe 
asthmatics 
Randomized controlled trials Rates of OCS bursts ≥ 5d, 
ED discharge vs 
admissions, need for ICU, 
adverse events 
Prevention To assess the benefits of 
measures such as nocturnal 
temperature controlled laminar 
flow 
Randomized controlled trials Rates of OCS bursts ≥ 5d, 
ED discharge vs 
admissions, need for ICU, 
adverse events 
Prevention to assess the use of biologics 
in the setting of acute 
exacerbation 
Randomized controlled trials Rates of relapses, speed of 
recovery, disease 
associated and hospital 
acquired-adverse events, 
quality of life 
From the 
patients’ 
perspective 
Overall, to find treatments for 
patients not responding well to 
currently available medications 
and treatments plans 
Randomized controlled trials 
in non eligible patients to 
existing drugs (low T2, 
failure of currently available 
biologics for example) 
Rates of OCS bursts ≥ 5d, 
ED discharge vs 
admissions, need for ICU, 
adverse events 
 
  
 
Table 6. 
Section 
no 
Section title Keypoints 
1 Definitions 
A definition based on five days of OCS is 
preferred to three to better fit with the 
recognized harmfulness of cumulative doses of 
OCS; a composite score assessing risk factors 
(age, comorbidities, history) would be helpful. 
2 
Triggers and risk 
factors 
Within trajectories of asthma, the frequent 
exacerbator phenotype is a reality, and is more 
frequently associated with a T2 pattern 
2A 
Assessment of risk,  
What is cause and 
what is effect 
T2 inflammation and lack of adequate 
treatment more likely exposes to exacerbation 
rather than the opposite.   
2B 
Modifiable vs non-
modifiable factors & 
Mathematical models 
Viral infections are now considered 
modifiable, associated with prevention of 
noxious environmental exposures.  
2C 
Risk Factors and 
epidemiology, 
pheno/geno/endotypes 
Susceptibility to severe exacerbations is not 
always shared with susceptibility to asthma 
severity. Low T2 asthma and other newly 
identified endotypes are currently orphans of 
targeted drugs. 
2D 
Personality type – 
Gender, Psychosocial 
factors. Perception, 
Compliance/adherence 
Multidisciplinary approaches may help in 
identifying and managing better patients at risk 
of death, ICU admission and severe 
exacerbations 
2E Virus / Allergens 
Rhinoviruses are ideal culprit fostering severity 
of exacerbations amplifyable by allergens. No 
dedicated treatment or preventive strategy 
currently exist. 
2F 
Environmental air 
pollution 
indoor/outdoor 
pollution & 
occupational factors 
Although obvious, the environmental impact is 
under-recognized and occupational factors 
insufficiently assessed and evidenced in 
practice. 
2G 
Drugs & irritants / 
Overdose of 2-
agonists 
Dangers of high SABA use includes worsening 
of asthma itself.  
3 Acute Management 
Systemic corticosteroids and bronchodilators 
are still the cornerstones of the acute 
management. Because some asthma deaths are 
not preventable, there is a place to develop new 
drugs on top of standard of care 
4 Prevention 
Inhaled corticosteroids +/- bronchodilators and 
in eligible patients with more severe disease 
biologics prevent severe exacerbations. 
5 
ELF Patient 
perspective 
The currently available treatments and supports 
are not working well enough for all. More 
research and partnership are needed. 
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